Loading
A phase 3 trial of Zirconium-89 girentuximab run by Telix Pharmaceuticals (Innovations) Pty Limited in renal cell carcinoma, now recruiting.
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study is a phase 3 interventional study registered as NCT06750419 by Telix Pharmaceuticals (Innovations) Pty Limited, with 82 participants planned, started 2024-11-06. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CAIX PET (89Zr-girentuximab), Telix Pharmaceuticals, Clear cell renal cell carcinoma.
Shares CAIX PET (89Zr-girentuximab), Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares CAIX PET (89Zr-girentuximab), Telix Pharmaceuticals, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/